Appendix 4C - Quarterly - 31 March 2024
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The report highlights the successful completion of a GMP production run and positive preclinical data regarding the use of deoxymabs for treating autoimmune diseases. The report also outlines ongoing business development efforts and the establishment of a Master Cell Bank for further product development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Patrys
- Positive preclinical data for deoxymabs in vasculitis
- Appendix 4D - Half Year Accounts - 31 December 2023
- Appendix 4C - Quarterly - 31 December 2023
- GMP Production of PAT-DX1 Next Quarter
- Appendix 4C - Quarterly - 30 September 2023
Later from Patrys
- Update on GMP manufacturing run of PAT-DX1
- Appendix 4C - Quarterly - 30 June 2024
- Further update on PAT-DX1 GMP manufacturing run
- Appendix 4E and 2024 Annual Report
- PAT-DX1 GMP specification testing update
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys